Akero Therapeutics reported positive Phase 2b trial results for EFX, showing fibrosis improvement in compensated cirrhosis due to MASH.
Quiver AI Summary
Akero Therapeutics recently presented results from its Phase 2b SYMMETRY trial at the EASL Congress 2025, showcasing the efficacy of efruxifermin (EFX) in improving fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH). The trial demonstrated significant fibrosis reduction in patients treated with EFX compared to placebo, with 39% of EFX 50mg patients showing improvement at 96 weeks. The results suggest that EFX not only reverses fibrosis but also maintains safety and tolerability, which is critical for patients facing poor prognosis with current treatment options limited mainly to liver transplants. Akero is advancing EFX through Phase 3 studies, further evaluating its potential across various stages of MASH and emphasizing the urgent need for effective therapies in this patient population.
Potential Positives
- Presented positive results from the Phase 2b SYMMETRY trial, demonstrating efruxifermin (EFX)'s potential to improve fibrosis in compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH), marking significant progress in a high unmet medical need.
- EFX is differentiated as the first treatment to demonstrate fibrosis reversal in patients with cirrhosis due to MASH, which could establish it as a groundbreaking therapy in this area.
- Data indicated a notable improvement in fibrosis among patients treated with EFX compared to placebo, with 39% of patients showing fibrosis improvement, potentially positioning the drug favorably for regulatory and market approval.
Potential Negatives
- The primary endpoint of the SYMMETRY study showed numerical improvement but not statistically significant differences at Week 36, which may raise concerns about the drug's effectiveness.
- The press release includes cautionary statements regarding the uncertain nature of forward-looking statements, indicating potential risks that could negatively impact the company's future performance and the development of EFX.
- Serious adverse events were reported, although deemed unrelated to the study drug; this could still affect investor perception regarding the safety profile of EFX.
FAQ
What are the main findings from the SYMMETRY trial?
The SYMMETRY trial demonstrated that efruxifermin (EFX) can significantly reduce fibrosis in compensated cirrhosis caused by MASH.
What is efruxifermin (EFX) used for?
EFX is being developed as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) and its complications, including fibrosis.
How effective is EFX compared to placebo in the trial?
In the SYMMETRY trial, 39% of EFX-treated patients showed fibrosis improvement versus 15% in placebo-treated patients.
What is the risk of compensated cirrhosis due to MASH?
Patients with compensated cirrhosis due to MASH face a 50% chance of dying within five years without a liver transplant.
How does EFX improve patient outcomes in the trial?
EFX shows promising anti-fibrotic activity, leading to fibrosis reduction without worsening of MASH, indicating significant potential benefits for patients.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AKRO Insider Trading Activity
$AKRO insiders have traded $AKRO stock on the open market 68 times in the past 6 months. Of those trades, 4 have been purchases and 64 have been sales.
Here’s a breakdown of recent trading of $AKRO stock by insiders over the last 6 months:
- G. WALMSLEY GRAHAM has made 4 purchases buying 400,000 shares for an estimated $18,387,921 and 0 sales.
- CATRIONA YALE (Chief Development Officer) has made 0 purchases and 17 sales selling 153,296 shares for an estimated $7,668,122.
- ANDREW CHENG (President and CEO) has made 0 purchases and 14 sales selling 154,593 shares for an estimated $6,660,928.
- TIMOTHY ROLPH (Chief Scientific Officer) has made 0 purchases and 19 sales selling 96,634 shares for an estimated $4,673,005.
- JONATHAN YOUNG (Chief Operating Officer) has made 0 purchases and 8 sales selling 83,110 shares for an estimated $3,487,223.
- PATRICK LAMY (Senior VP, Commercial Strategy) has made 0 purchases and 4 sales selling 7,925 shares for an estimated $390,850.
- WILLIAM RICHARD WHITE (Chief Financial Officer) has made 0 purchases and 2 sales selling 3,493 shares for an estimated $117,074.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AKRO Hedge Fund Activity
We have seen 116 institutional investors add shares of $AKRO stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALKEON CAPITAL MANAGEMENT LLC removed 1,563,736 shares (-47.0%) from their portfolio in Q4 2024, for an estimated $43,503,135
- CITADEL ADVISORS LLC added 1,204,992 shares (+803.9%) to their portfolio in Q4 2024, for an estimated $33,522,877
- JANUS HENDERSON GROUP PLC removed 1,043,239 shares (-14.7%) from their portfolio in Q4 2024, for an estimated $29,022,908
- RTW INVESTMENTS, LP added 940,388 shares (+15.9%) to their portfolio in Q4 2024, for an estimated $26,161,594
- DEEP TRACK CAPITAL, LP added 800,216 shares (+116.0%) to their portfolio in Q4 2024, for an estimated $22,262,009
- BALYASNY ASSET MANAGEMENT L.P. added 649,134 shares (+inf%) to their portfolio in Q4 2024, for an estimated $18,058,907
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 630,048 shares (-48.5%) from their portfolio in Q4 2024, for an estimated $17,527,935
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AKRO Analyst Ratings
Wall Street analysts have issued reports on $AKRO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 02/02/2025
- Citigroup issued a "Buy" rating on 11/18/2024
To track analyst ratings and price targets for $AKRO, check out Quiver Quantitative's $AKRO forecast page.
Full Release
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands.
“Compensated cirrhosis due to MASH remains a high unmet medical need, leaving patients with a poor prognosis and currently no effective treatment options beyond liver transplant,” said Kitty Yale, chief development officer of Akero. “These data presented at the EASL Congress 2025 differentiate EFX from other approved or investigational MASH treatments as the first to demonstrate fibrosis reversal in patients with MASH caused by cirrhosis. We look forward to continuing evaluation of EFX across all stages of MASH in our Phase 3 SYNCHRONY program.”
“Patients with cirrhosis caused by MASH could face a 50 percent chance of dying within five years without a liver transplant,” said Mazen Noureddin, M.D., Professor of Medicine and Transplant Hepatologist at Houston Methodist Hospital, and principal investigator for the SYMMETRY study. “EFX’s powerful anti-fibrotic activity, as observed in the Phase 2b SYMMETRY trial and currently being evaluated in Phase 3, has the potential to be the most substantial medical breakthrough in my career as a treating physician.”
Week 96 data presented from SYMMETRY, a Phase 2b trial evaluating the efficacy and safety of Akero’s lead product candidate, EFX, in patients with biopsy-confirmed compensated cirrhosis (F4) due to MASH, showed fibrosis reduction without MASH worsening by both completer and intent-to-treat (ITT) analyses after 96 weeks. In the pre-specified analysis of patients with baseline and week 96 biopsies (N=134), 39% of patients treated with EFX 50mg had fibrosis improvement compared to 15% of placebo-treated patients (p=0.009). In the ITT population (N=181), with missing week 96 biopsies treated as non-responders, 29% of patients in the EFX 50mg group experienced this improvement, compared to 11% for placebo (p=0.031). The primary endpoint of the SYMMETRY study was ≥1 stage fibrosis improvement with no worsening of MASH at Week 36. A numerical improvement was observed in the EFX groups vs. placebo at Week 36 but the differences were not statistically significant.
Summary of Week 96 Fibrosis Improvement without MASH Worsening Secondary Endpoint
Primary Analysis (N=134) 1 | ITT Analysis (N=181) 2 | |||||
Histology Endpoint 3 (Proportion of Patients) |
Placebo
(N=47) |
EFX 28mg
(N=41) |
EFX 50mg
(N=46) |
Placebo
(N=61) |
EFX 28mg
(N=57) |
EFX 50mg
(N=63) |
≥1 stage fibrosis improvement without worsening MASH (%) | 15 | 29 | 39 * * | 11 | 21 | 29 * |
1
All patients with baseline and week 96 biopsies
2
The 47 randomized and dosed patients who had missing biopsies at week 96 are treated as non-responders in the ITT analysis (without imputation).
3
Biopsies scored independently by two pathologists; third available to adjudicate (which was not required)
*
p<0.05,
**
p<0.01, versus placebo (Cochran-Mantel-Haenszel test).
Comparison of the proportion of patients with a fibrosis reduction at Week 36 and Week 96 in the pre-specified analysis of patients with baseline and week 96 biopsies, showed more than a doubling of placebo-adjusted treatment effect for the EFX 50mg group, from 10% to 24%. This increase in effect size shows the importance of longer treatment with EFX for patients with compensated cirrhosis (F4) as compared to responses observed in trials of EFX in patients with earlier stage fibrosis (F2 or F3).
The larger treatment effect observed after 96 weeks is corroborated by changes in noninvasive measures of liver fibrosis and injury. For example, two key non-invasive measures of the extent of fibrosis development in the whole liver, ELF test score and liver stiffness by Fibroscan, showed continuing improvement over 96 weeks for the 50mg EFX group.
Newly presented analyses showed EFX’s potential to improve fibrosis among patients with compensated cirrhosis across key subgroups. Patients responded to EFX 50mg after 96 weeks regardless of type 2 diabetes status or treatment with GLP-1 medications or statins at baseline.
The safety and tolerability profile of EFX was consistent with previous trials. The most frequent adverse events with EFX were gastrointestinal (diarrhea, nausea, increased appetite) and most were mild to moderate and transient. All serious adverse events were deemed to be unrelated to study drug.
Details for the presentation are as follows:
Title:
Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY)
Speaker:
Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Date/Time:
Friday, May 9, 2025, from 12:15 pm – 12:30 pm CET
Abstract Identifier:
GS-012
Oral Session:
General Session 2
About Cirrhosis Due to MASH
Cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis) is a life-threatening disease with high risk of liver failure, cancer, and death. By 2030, an estimated 3 million Americans are projected to have MASH cirrhosis, which is the fastest growing cause of liver transplants and liver cancer in the United States and Europe.
About the SYMMETRY Study
SYMMETRY was a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in adult patients with biopsy-confirmed compensated cirrhosis (F4, Child-Pugh A) due to MASH. The study randomized 182 patients, and 181 received once-weekly subcutaneous EFX 28mg or 50mg, or placebo for 96 weeks. The primary efficacy endpoint was the proportion of patients with ≥1 stage fibrosis improvement without worsening of MASH at Week 36. Secondary efficacy measures at Week 96 included ≥1 stage fibrosis improvement without worsening of MASH, MASH resolution, change from baseline in liver enzymes, noninvasive markers of liver fibrosis, serum markers of glucose and lipid metabolism, as well as safety and tolerability measures.
About EFX
Efruxifermin (EFX), Akero’s lead product candidate for MASH, is currently being evaluated in three ongoing Phase 3 studies. In multiple Phase 2 studies, EFX has been observed to reverse fibrosis (including compensated cirrhosis), resolve MASH, reduce non-invasive markers of fibrosis and liver injury, and improve insulin sensitivity and lipoprotein profile. This holistic profile offers the potential to address the complex, multi-system disease state of all stages of MASH, including improvements in risk factors linked to cardiovascular disease – the leading cause of death among MASH patients. Engineered to mimic the biological activity profile of native FGF21, EFX is designed to offer convenient once-weekly dosing and has been generally well-tolerated in clinical trials to date.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, statements regarding Akero’s business plans and objectives; the potential therapeutic effects and anti-fibrotic activity of EFX, as well as the dosing, safety and tolerability of EFX, the future potential and long-term benefits of EFX following the preliminary topline week 96 results of Akero’s Phase 2b SYMMETRY study and the ongoing SYNCHRONY Phase 3 program. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Akero’s product candidate development activities and planned clinical trials; Akero’s ability to execute on its strategy; positive results from any of its clinical studies may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Akero’s ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors'' in Akero’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in Akero’s other filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Akero undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
[email protected]
Media Contact:
Peg Rusconi
Deerfield Group
617.910.6217
[email protected]